U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07223567) titled 'Phase II Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer' on Oct. 30.
Brief Summary: This is a prospective single-center, single-arm, open-label, phase II study evaluating the safety, activity, and efficacy of regorafenib in combination with lorigerlimab for the treatment of patients with regrowing or locally recurrent pMMR/MSS localized rectal cancer following TNT.
Study Start Date: April 30, 2026
Study Type: INTERVENTIONAL
Condition:
Rectal Cancer
Rectal Cancer Recurrent
Intervention:
DRUG: Regorafenib
Given by mouth
DRUG: Lorigerlimab
Give by IV infus...